// App-Quantinova.ai

: An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Researchers

Presenter

  • Ajay K. Nooka

Principal Investigators

  • Cesar Rodriguez

  • Andrzej Jakubowiak

  • Yvonne A. Efebera

  • Brandi Reeves

  • Tanya M. Wildes

  • Sarah A. Holstein

  • Larry D. Anderson

  • Ashraf Z. Badros

  • Leyla O. Shune

  • Ajai Chari

  • Huiling Pei

  • Annelore Cortoos

  • Sharmila Patel

  • Thomas S. Lin

  • Paul G. Richardson

  • Saad Usmani

  • Peter M. Voorhees

Medical Centers

  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • University of Chicago Medical Center, Chicago, IL

  • OhioHealth, Columbus, OH

  • Levine Cancer Institute, Atrium Health Wake Forest Baptist, Charlotte, NC

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Winship Cancer Institute of Emory University Hospital, Atlanta, GA

  • Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

  • University of North Carolina at Chapel Hill, Chapel Hill, NC

  • Division of Hematologic Malignancies and Cellular Therapeutics (HMCT), University of Kansas Medical Center, Kansas City, KS

  • Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA

  • Myeloma, Waldenstrom's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX

  • Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA

  • Memorial Sloan Kettering Cancer Center, New York, NY

  • Greenbaum Cancer Center, University of Maryland, Baltimore, MD

Locations

  • United States

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • daratumumab Intravenous

  • Bortezomib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved